Table 2.
Baseline characteristics.
| Study | Total | 90Y-J591 | 177Lu-J591 |
|---|---|---|---|
| Patients, n (%) | 150 (100) | 29 (19.3) | 121 (80.7) |
| Age, years (range) | 70.7 (44.5–96) | 70 (48–84.7) | 71 (44.5–96) |
| Prior radiation to any location, n (%) | 77 (51.3) | 12 (41.4) | 65 (53.7) |
| Prior radiation to prostate/prostate bed, n (%) | 62 (41.3) | 10 (34.5) | 52 (42.9) |
| Cytotoxic chemotherapy prior to radiolabeled-J591, n (%) | 67 (44.6) | 14 (48.2) | 53 (43.8) |
| Both chemotherapy and radiation prior to radiolabeled-J591, n (%) | 35 (23.3) | 4 (13.8) | 31 (25.6) |
| Bony metastases, n (%) | 129 (86) | 20 (69) | 109 (90.1) |
| Pulmonary metastases, n (%) | 23 (15.3) | 2 (6.9) | 21 (17.4) |
| Hepatic metastasis, n (%) | 12 (8) | 1 (3.5) | 11 (9.1) |
| Lymph node metastasis, n (%) | 81 (54) | 14 (48.3) | 67 (55.4) |